Workshop B: Beyond Intrathecal Administration, What is the Next Step in Less-Invasive Oligonucleotide Delivery?
Time: 7:30 am
day: Pre-Conference Workshop Day Track B
Details:
While intrathecal delivery has offered an opportunity for oligonucleotides to be administered directly to the CNS, the technique remains highly invasive with a significant risk of postoperative infections and a need for multiple doses per year. This will inherently limit treatment uptake and clinical utility especially for large scale patient demographics. Alternative non-invasive routes of administration for oligonucleotide therapeutics are under investigation, including receptor mediated systemic delivery and the promising nose-to-brain delivery that offers clinically translatable and safer alternatives.
Join this workshop to:
- Learn of the different modalities for invasive and non-invasive oligonucleotide delivery to the CNS, including preclinical and clinical examples.
- Understand nose-to-brain delivery of oligonucleotides using an innovative Minimally Invasive Nasal Depot (MIND) approach pioneered by the workshop presenters.
- Evaluate different oligonucleotide therapeutic delivery examples in naïve and disease-specific rodent models.
- Appreciate the pathways to clinical translation of MIND for treatment of neurological diseases.
